H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans

Journal of Virology

Volumn 85, Issue 21, 2011, Pages 10945-10954

  Khurana, Surender ^a   Wu, Jian ^a   Verma, Nitin ^a   Verma, Swati ^a   Raghunandan, Ramadevi ^a   Manischewitz, Jody ^a   King, Lisa R ^a   Kpamegan, Eloi ^b   Pincus, Steven ^b   Smith, Gale ^b   Glenn, Gregory ^b   Golding, Hana ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NOVAVAX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

H5N1 VIRUS LIKE PARTICLE VACCINE; HEMAGGLUTININ 1; HEMAGGLUTININ 1 RECEPTOR; HEMAGGLUTININ 2; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MATRIX 1 PROTEIN; MATRIX PROTEIN; NEUTRALIZING ANTIBODY; PLACEBO; SIALIC ACID; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS SIALIDASE;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CLADISTICS; CONTROLLED STUDY; CROSS REACTION; DOSE RESPONSE; DRUG MEGADOSE; DRUG WITHDRAWAL; ENZYME INHIBITION; GENE LIBRARY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MYALGIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CROSS REACTIONS; EPITOPE MAPPING; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; NEURAMINIDASE; NEUTRALIZATION TESTS; PROTEIN BINDING; SPODOPTERA; VACCINES, VIROSOME; VIRAL PROTEINS;

AVES; AVIAN INFLUENZA VIRUS; HEXAPODA; ORTHOMYXOVIRIDAE;

EID: 80055113889     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05406-11     Document Type: Article

References (52)

1. Beigel, J. H., J. Voell, C. Y. Huang, P. D. Burbelo, and H. C. Lane. 2009. Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. J. Infect. Dis. 200:501-509.
2. Bernstein, D. I., et al. 2008. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 197: 667-675.
3. Bosch, B. J., et al. 2010. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J. Virol. 84:10366-10374.
4. Bright, R. A., et al. 2008. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 3:e1501.
5. Bright, R. A., et al. 2007. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25:3871-3878.
6. Brown, D. R., et al. 2011. The humoral response to Gardasil(R) over four years as defined by Total IgG and competitive Luminex immunoassay. Hum. Vaccin. 7:230-238.
7. Colman, P. M. 1992. Structural basis of antigenic variation: studies of influenza virus neuraminidase. Immunol. Cell Biol. 70:209-214.
8. Crawford, J., et al. 1999. Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine 17:2265-2274.
9. Deschuyteneer, M., et al. 2010. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum. Vaccin. 6:407-419.
10. Eichelberger, M., et al. 2008. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 26:4299-4303.
11. Eichelberger, M. C., A. Hassantoufighi, M. Wu, and M. Li. 2008. Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay. Virol. J. 5:109.
12. Gambotto, A., S. M. Barratt-Boyes, M. D. de Jong, G. Neumann, and Y. Kawaoka. 2008. Human infection with highly pathogenic H5N1 influenza virus. Lancet 371:1464-1475.
13. Gavrilov, V., et al. 2011. Influenza virus-like particles as a new tool for vaccine immunogenicity testing: validation of a neuraminidase neutralizing antibody assay. J. Virol. Methods 173:364-373.
14. Katz, J. M., et al. 1999. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J. Infect. Dis. 180:1763-1770.
15. Kemp, T. J., et al. 2011. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29:2011-2014.
16. Khurana, S., et al. 2010. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2:15ra5.
17. Khurana, S., et al. 2011. Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines. Vaccine 29:5657-5665.
18. Khurana, S., et al. 2009. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med. 6:e1000049.
19. Khurana, S., et al. 2011. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3:85ra48.
20. Khurana, S., et al. 2011. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and crossprotective immunity in ferrets. J. Virol. 85:1246-1256.
21. Khurana, S., et al. 2010. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS One 5:e11548.
22. Lakey, D. L., et al. 1996. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J. Infect. Dis. 174:838-841.
23. Landry, N., et al. 2010. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 5:e15559.
24. Langley, J. M., et al. 2010. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J. Infect. Dis. 201:1644-1653.
25. Latham, T., and J. M. Galarza. 2001. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol. 75:6154-6165.
26. Li, X., et al. 2006. Essential sequence of influenza neuraminidase DNA to provide protection against lethal viral infection. DNA Cell Biol. 25:197-205.
27. Lopez-Macias, C., et al. 2 August 2011. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine. doi: 10.1016/j.vaccine.2001.07.099.
28. Lu, H., et al. 2011. A rapid Flp-In system for expression of secreted H5N1 influenza hemagglutinin vaccine immunogen in mammalian cells. PLoS One 6:e17297.
29. Maass, D. R., and P. H. Atkinson. 1990. Rotavirus proteins VP7, NS28, and VP4 form oligomeric structures. J. Virol. 64:2632-2641.
30. Mahmood, K., et al. 2008. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26:5393-5399.
31. Mikell, I., et al. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7:e1001251.
32. Noad, R., and P. Roy. 2003. Virus-like particles as immunogens. Trends Microbiol. 11:438-444.
33. Noah, D. L., H. Hill, D. Hines, E. L. White, and M. C. Wolff. 2009. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin. Vaccine Immunol. 16:558-566.
34. Pancera, M., et al. 2010. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternaryspecific antibodies that effectively neutralize HIV-1. J. Virol. 84:8098-8110.
35. Potier, M., L. Mameli, M. Belisle, L. Dallaire, and S. B. Melancon. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferylalpha-D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296.
36. Pushko, P., et al. 2010. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 28:4771-4776.
37. Pushko, P., et al. 2005. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23:5751-5759.
38. Roldao, A., M. C. Mellado, L. R. Castilho, M. J. Carrondo, and P. M. Alves. 2010. Virus-like particles in vaccine development. Expert Rev. Vaccines 9:1149-1176.
39. Scheid, J. F., et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640.
40. Simmons, C. P., et al. 2007. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 4:e178.
41. Straight, T. M., M. G. Ottolini, G. A. Prince, and M. C. Eichelberger. 2008. Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats. Virol. J. 5:44.
42. Treanor, J. J., et al. 1996. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J. Infect. Dis. 173:1467-1470.
43. Treanor, J. J., J. D. Campbell, K. M. Zangwill, T. Rowe, and M. Wolff. 2006. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354:1343-1351.
44. Treanor, J. J., et al. 2006. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J. Infect. Dis. 193:1223-1228.
45. Treanor, J. J., et al. 2001. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-1737.
46. Tulip, W. R., J. N. Varghese, W. G. Laver, R. G. Webster, and P. M. Colman. 1992. Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex. J. Mol. Biol. 227:122-148.
47. Tulip, W. R., J. N. Varghese, R. G. Webster, W. G. Laver, and P. M. Colman. 1992. Crystal structures of two mutant neuraminidase-antibody complexes with amino acid substitutions in the interface. J. Mol. Biol. 227:149-159.
48. Walker, L. M., et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
49. Wang, K., et al. 2006. Expression and purification of an influenza hemagglutinin- one step closer to a recombinant protein-based influenza vaccine. Vaccine 24:2176-2185.
50. Wei, C. J., et al. 2008. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J. Virol. 82:6200-6208.
51. Weldon, W. C., et al. 2010. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One 5:e12466.
52. Wrammert, J., et al. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208:181-193.